文献速递前列腺癌

PSA与PSA倍增时间预测生化复发前列腺癌的18F-DCFPyL PET/CT表现

Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.
PubMed 文献 · J Urol · 2020-04-06

本研究回顾性分析108例根治性前列腺切除术后生化复发患者,评估Gleason评分、血清PSA及PSA倍增时间与18F-DCFPyL PET/CT检出病灶及盆腔局限性疾病的关系。结果显示PSA与阳性影像正相关且与盆腔局限病变负相关,PSA倍增时间不预测总体检出但较长倍增时间与盆腔局限病变相关。

要点

  • 血清PSA升高与18F-DCFPyL PET/CT阳性表现独立相关。
  • PSA>2.0-5.0 ng/ml者盆腔局限病变概率显著低于≤0.5 ng/ml者。
  • PSA倍增时间≥9或≥12个月与盆腔局限病变显著相关。

核心结论

  • 绝对PSA水平与PSMA靶向成像阳性表现正相关,与盆腔局限病变负相关。
  • PSA倍增时间不预测总体病灶检出,但较长倍增时间与盆腔局限前列腺癌相关。

研究设计与样本

  • 回顾性分析108例根治性前列腺切除术后生化复发且接受18F-DCFPyL PET/CT的患者。
  • 收集PET阳性表现及盆腔局限病变数据,探索Gleason评分、PSA和PSA倍增时间的关联。

主要发现

  • 血清PSA作为连续变量与阳性成像相关(OR 3.08,95%CI 1.60-7.95,p=0.005)。
  • PSA>2.0-5.0 ng/ml vs ≤0.5 ng/ml与阳性成像相关(OR 16.92,95%CI 3.13-315.81,p=0.008)。
  • PSA>2.0-5.0 ng/ml者盆腔局限病变概率显著低于≤0.5 ng/ml者(OR 0.21,95%CI 0.06-0.69,p=0.013)。
  • PSA倍增时间≥9个月与盆腔局限病变相关(OR 4.20,95%CI 1.57-11.89,p=0.005)。
  • PSA倍增时间≥12个月与盆腔局限病变相关(OR 3.03,95%CI 1.12-8.76,p=0.033)。

关键数值与推荐

  • PSA>2.0-5.0 ng/ml相比≤0.5 ng/ml,阳性成像OR 16.92(95%CI 3.13-315.81,p=0.008)。
  • PSA>2.0-5.0 ng/ml相比≤0.5 ng/ml,盆腔局限病变OR 0.21(95%CI 0.06-0.69,p=0.013)。
  • PSA倍增时间≥9个月,盆腔局限病变OR 4.20(95%CI 1.57-11.89,p=0.005)。
  • PSA倍增时间≥12个月,盆腔局限病变OR 3.03(95%CI 1.12-8.76,p=0.033)。

临床怎么用

  • 生化复发前列腺癌患者行18F-DCFPyL PET/CT前可参考PSA水平预判检出概率。
  • PSA较低且倍增时间较长者,影像发现盆腔局限病变的可能性较高。

局限性

  • 回顾性研究设计。
  • 单中心样本量108例。
  • 未报告Gleason评分与总体阳性成像或盆腔局限病变的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography/computerized tomography may offer superior image quality and sensitivity for the detection of biochemically recurrent prostate cancer. We examined the association of Gleason sum, serum prostate specific antigen and prostate specific antigen doubling time with any detectable and pelvic confined disease in patients with biochemically recurrent prostate cancer. MATERIALS AND METHODS: Data from 108 patients with biochemically recurrent prostate cancer after radical prostatectomy who underwent prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography/computerized tomography were analyzed. Data were collected on positive positron emission tomography findings as well as pelvic confined disease. Associations between Gleason sum, prostate specific antigen and prostate specific antigen doubling time were retrospectively explored. RESULTS: Serum prostate specific antigen was associated with positive prostate specific membrane antigen targeted imaging as continuous (OR 3.08, 95% CI 1.60-7.95, p=0.005) and categorical values (ie prostate specific antigen greater than 2.0 to 5.0 vs 0.5 ng/ml or less, OR 16.92, 95% CI 3.13-315.81, p=0.008). No relationship between Gleason sum or prostate specific antigen doubling time with overall positive imaging was observed. Patients with a prostate specific antigen greater than 2.0 to 5.0 ng/ml were significantly less likely to be diagnosed with pelvic confined disease compared with the 0.5 ng/ml or less subgroup (OR 0.21, 95% CI 0.06-0.69, p=0.013). A prostate specific antigen doubling time of 9 months or more (OR 4.20, 95% CI 1.57-11.89, p=0.005) or prostate specific antigen doubling time of 12 months or more (OR 3.03, 95% CI 1.12-8.76, p=0.033) was significantly associated with pelvic confined disease. No relationship between Gleason sum and pelvic confined disease was observed. CONCLUSIONS: Absolute prostate specific antigen was positively associated with the presence of findings on prostate specific membrane antigen targeted imaging and negatively associated with pelvic confined disease. Prostate specific antigen doubling time did not predict for overall disease detection, but long prostate specific antigen doubling times were associated with pelvic confined prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Markowski MC, Sedhom R, Fu W, et al. Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. J Urol. 2020. PMID: 32250727. doi:10.1097/JU.0000000000001064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。